ECS Botanics (ASX:ECS) - Managing Director & Founder, Alex Keach
Managing Director & Founder, Alex Keach
Sourced: The Examiner
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Medicinal cannabis company ECS Botanics (ECS) has entered into a term sheet agreement with Australian-Canadian pharmaceutical, MediPharm Labs
  • The agreement will see ECS supply cannabis inputs to MediPharm’s wholly-owned subsidiary MediPharm Labs Australia
  • In turn, MediPharm will supply ECS with harvesting and production equipment to aid its commercial cannabis extraction operations in Tasmania
  • The three year supply agreement is due to commence November 2021 with price point reviews to take place on a half-yearly basis henceforth
  • A company spokesperson noted the supply and equipment technology transfer agreement components are not mutually exclusive and are subject to further definitive documentation
  • Overall, however, the arrangements are considered an exciting and mutually beneficial supply chain relationship for both parties
  • Investors have responded favourably to the announcement, with ECS shares up 7.32 per cent trading at 4.4 cents each

Medicinal cannabis company ECS Botanics (ECS) has entered into a term sheet agreement with Australian-Canadian pharmaceutical, MediPharm Labs.

The binding term sheet agreement and technology transfer purchase agreements are between ECS and the Canadian Stock Exchange lister’s Australian subsidiary, Medipharm Labs Australia.

Under the binding term sheet agreement, ECS will supply cannabis inputs, such as flower and crude resin extract, to aid the creation of formulated cannabis products.

The equipment technology transfer purchase agreement component will see MediPharm Australia provide harvesting and extraction equipment and technologies for ECS’ commercial harvesting operations.

The three year supply agreement is due to commence November 2021 with price point reviews to take place on a half-yearly basis henceforth.

A company spokesperson noted the supply and equipment technology transfer agreements are not mutually exclusive and are subject to further definitive documentation.

Overall, however, the arrangements are considered an exciting and mutually beneficial supply chain relationship for both parties.

Investors have responded favourably to the announcement, with ECS shares up 7.32 per cent trading at 4.4 cents each at 7:59 AEDT.

ECS by the numbers
More From The Market Online

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…

Osteopore stock spikes 900% on Singapore and Vietnam approvals

Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…